Abstract Purpose: Repetitive ribosomal DNA (rDNA) genes are GC-rich clusters in the human genome.
States alone and about 16,210 deaths from the disease each year. Ovarian cancer is typically asymptomatic in early stages, and more than two thirds of patients present with late-stage disease. Despite therapeutic advances, 5-year survival rates are <30% for patients diagnosed with advanced-stage ovarian cancer. Clinicopathologic variables, such as Fédération Internationale des Gynaecologistes et Obstetristes (FIGO) stage, grade, and age, are currently used as prognostic indicators but the ability of these to predict patient survival remains fairly imprecise. Thus, a better understanding of the molecular pathogenesis of ovarian cancer may lead to the development of more sensitive and reliable prognostic markers.
Aberrant DNA methylation, an epigenetic hallmark of many cancers, plays an important role in tumorigenesis (2, 3) . Several groups, including ours (4, 5) , have shown that tumor suppressor genes can become transcriptionally silenced by CpG island hypermethylation in many different cancer types (6, 7) , including ovarian cancer (8, 9) . In addition to single-copy genes, normally unexpressed repeat sequences are also subjected to this epigenetic alteration during carcinogenesis (10 -12) . We have found that ribosomal DNA (rDNA), tandemly expressed repeats, can display altered DNA methylation patterns in cancer (13, 14) . About 800 copies of rDNA, located on the short arm of acrocentric chromosomes, are present in the human genome (15) . The GC-rich transcriptional domains of rDNA are generally unmethylated in normal cells and associated with active expression of 18S, 5.8S, and 28S RNA subunits (16, 17) .
Previously, we showed that rDNA genes are densely methylated in breast and endometrial cancers, suggesting that rDNA hypermethylation plays an important role in tumorigenesis (13, 14) . However, semiquantitative Southern blotting was used in those studies, which is labor-intensive and requires a large amount of DNA (10 Ag). Therefore, in the present study, we developed a PCR-based assay for rapid, quantitative analysis of cellular rDNA methylation. We used this assay to analyze rDNA methylation levels in ovarian cancers obtained from pathology archives. Our results indicate for the first time that the level of rDNA hypermethylation is associated with prolonged progression-free survival of ovarian cancer patients. We suggest that rDNA methylation represents a novel biomarker for the prognosis of ovarian cancer.
Materials and Methods
Patient DNA samples. Seventy-four formalin-fixed, paraffin-embedded tumor blocks from patients diagnosed with advanced-stage epithelial ovarian cancer between 1990 and 2001 were obtained from the Ohio State University Medical Center (Columbus, OH). Tumor areas were reviewed and confirmed by the appointed pathologist (P.W.) who selected the best representative areas with 100% invasive papillary serous carcinoma for microdissection. Area with necrosis and benign-appearing stroma were excluded. As control references, 11 normal ovarian surface epithelia and 9 histologically normal ovarian tissue samples adjacent to tumor sites were obtained from Indiana University School of Medicine (Bloomington, IN), Cooperative Human Tissue Network (Columbus, OH), and Western Infirmary and Stobhill General Hospital (Glasgow, United Kingdom). Clinicopathologic data for the tissues samples are summarized in Table 1 .
Cell culture and demethylation treatment. Ovarian cancer cell lines A2780/MCP3 and A2780/CP70 were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum. For demethylating experiments, 5 Â 10 5 cells were seeded in 90-mm plates and treated with 5 Amol/L 5V -aza-2V -deoxycytidine (5-azaDC; Sigma, St. Louis, MO) for 72 hours.
DNA extraction. Archival DNA was extracted by high heat and alkaline conditions as described by Shi et al. (18) . Briefly, paraffin cores were autoclaved at 120jC for 20 minutes in the presence of 500 AL of 1% SDS and 0.1 mol/L NaOH (pH f12.5). After cooling to room temperature, the samples were extracted and purified by phenolchloroform extraction. The DNA pellet was dissolved in 50 AL distilled water and stored at À20jC until use. Genomic DNAs of fresh-frozen normal adjacent tissues were extracted using QIAamp tissue kit (Qiagen, Valencia, CA).
Bisulfite conversion and quantitative methylation-specific PCR. Genomic DNA (1 Ag) was bisulfite modified by EZ DNA Methylation Kit (Zymo Research, Orange, CA). The modified DNA was subject to real-time quantitative methylation-specific PCR using Bio-Rad iCyler (Bio-Rad, Hercules, CA). Each reaction contained 12.5 AL of 2Â SYBR Green supermix (Bio-Rad), 160 nmol/L of each primers, and 2 AL of bisulfite modified DNA in a total volume of 25 AL at 95jC for 10 minutes, 35 cycles of 95jC for 15 seconds, 60jC for 30 seconds, and 72jC for 30 seconds. Primers targeting the rDNA transcriptional domains were 18S forward, 5V TTTTTAGATGTTCGGGGTTGTACGC, and 18S reverse, 5VCCATCACGAATAAAATTCAACGAA (104 bp); 28S forward, TTTTAGATTAGACGTGGCGATTCG, and 28S reverse, GACGC-TAAACTCTTCCCTATTCACTCG (113 bp). b-actin was used to normalize for input DNA. A region of b-actin, devoid of any CpG dinucleotide, was amplified using the following primer sequences: h-actin forward, 5VTGGTGATGGAGGAGGTTTAGTAAGT, and h-actin reverse, 5V AACCAATAAAACCTACTCCTCCCTTAA (133 bp). The amount of methylated rDNA was determined by the threshold cycle number (C t ) for each sample against a standard curve generated by SssI-treated sperm DNA (Chemicon, Temecula, CA) and expressed as the ratio of the amount of rDNA to that of h-actin. Samples with a ratio of >0.5 were considered to have a high level of rDNA methylation (see Results). Table 1 . Association of rDNA methylation and clinicopathologic features of 74 ovarian cancer patients , and h-actin (ACTB) genes from standard (SssI-treated DNA) with different concentrations. The low C t achieved by 18S and 28S suggests that the assay is very sensitive (limit of f100 pg). The primers used for the interrogated region in all three genes yielded specific PCR products and no primer-dimers, which was confirmed by 10% PAGE (data not shown). Ribosomal DNA expression analysis by quantitative reverse transcription-PCR. Total RNA from cell lines was extracted using RNeasy Mini Kit (Qiagen). Total RNA (1 Ag) was treated with DNase I (amplification grade, Invitrogen) before first-strand cDNA synthesis using reverse transcriptase (Superscript II RT, Invitrogen). PCR reactions were carried out in a final volume of 25 AL containing 12.5 AL of SYBR Green PCR master mix (Applied Biosystems, Foster city, CA), 200 ng of each primer, and 2 AL of cDNA. 18S and 28S rDNAs and h-actin cDNA were amplified with the following condition: 95jC for 10 minutes, 35 cycles of 95jC for 15 minutes, 60jC for 30 se conds, and 72jC for 35 seconds using an ABI 7500 real-time PCR system (Applied Biosystems). The primer sequences were 18S forward, 5V -GGATGCGTGCATTTATCAGA, and reverse, 5V -GTTGATAGGGCAGACGTTCG; 28S forward, 5V GACCCGCTGAATTTAAGCAT, and reverse, 5V GCCTCGATCAGA-GCCTCGATCAGAAGGACTTG; h-actin forward, 5V TGCGTGACAT-TGCGTGACATTAAGGAGAAG, and reverse, 5V GCTCGTAGCTCTT-CTCCA. The amount of cDNA in a sample was determined by comparing the C t of the sample against a standard curve generated from a cDNA pool. The amount of h-actin in each sample was used for normalization. To validate the use of h-actin as an internal control, h-actin levels in both the mock-treated and 5-azaDC -treated Statistical analysis. Univariate survival analysis was determined using Cox proportional hazards model with rDNA methylation level as a continuous variable. The multivariate Cox proportional hazards model was done to determine the independent prognostic value of rDNA methylation level, stage, and age. Progression-free survival and overall survival were assessed by Kaplan-Meier analysis using log-rank test. Progression-free survival was defined as the duration from day of diagnosis or chemotherapy to detection of new lesions or progression of residual lesions. Overall survival was defined as the duration from day of diagnosis to death. Multiple agents including carboplatin, cisplatin, taxol, and etoposide were used as chemotherapeutic agents. rDNA methylation level at 0.5 gave the best discrimination between long-and short-survival groups and was thus used as a cutoff. Mann-Whitney U test was used to compare the clinicopathologic variables of the two patient groups. All statistical calculations were done using either statistical package SAS version 9.1 (SAS Institute, Inc., Cary, NC) or SPSS version 11.0 for windows (SPSS, Inc., Chicago, IL). P < 0.05 was considered significant.
Results and Discussion
Concurrent hypermethylation of 18S and 28S ribosomal genes is a frequent event in ovarian serous carcinomas. To quantitate methylation levels of 18S and 28S rDNA in ovarian cancer, we used a simple and sensitive quantitative methylation-specific PCR assay with SYBR Green as the reporting molecule for quantifying DNA methylation (19) . Two primer pairs, each targeting the transcriptional domains of 18S and 28S gene clusters, were used (Fig. 1A ) . Dissociation curves and amplification plots from real-time PCR confirmed that the amplification reactions were highly specific for the targeted regions (Fig. 1B) .
Late-stage ovarian tumors (n = 74) were analyzed by quantitative methylation-specific PCR. The median age at the time of diagnosis for our patient cohort was 58 years (range, 36-81 years). Forty-seven cases (63.5%) were at FIGO stage III and 27 cases (36.5%) were at FIGO stage IV. The results Short progression-free survival and overall survival groups are defined as survival of <12 months whereas long progression-free survival and overall survival groups are defined as survival of >84 months. Box, interquartile range which contains 50% of the measured variable.Thick horizontal line across the box, median value.Whiskers, maximum and minimum values. Table 1 . For control experiments, normal ovarian surface epithelia (n = 11) and histologically normal ovarian samples (n = 9) were analyzed by this quantitative assay. As shown in Table 1 , the mean methylation level of 28S rDNA was significantly higher in tumor samples than in both types of control samples; however, the level of 18S rDNA methylation was only significantly higher in tumors relative to normal ovarian surface epithelia. No association between rDNA hypermethylation and age (V60 versus >60 years) or clinical stage (stage III versus stage IV) was observed. However, 18S and 28S methylation levels were highly correlated (R 2 = 0.842; Fig. 2 ). Concurrent methylation of multiple single-copy genes has been observed in many tumor types (20, 21) , including ovarian cancer (8) . Although not fully understood, this nonrandom epigenetic phenomenon, commonly called CpG island methylator phenotype, may be due to dysregulation of trans elements in cancer cells (22 -24) . Alternatively, a defect of cis elements (or methylation centers) could occur, allowing the spread of methylation from this center to the adjacent CpG site(s) (24) . To our knowledge, this is the first report of concurrent hypermethylation of 18S and 28S ribosomal genes in ovarian cancer, which are located in tandem in the rDNA cluster. Thus, a spreading phenomenon may explain the nature of concurrent hypermethylation of these two rDNA genes.
Higher ribosomal DNA methylation level predicts better survival in ovarian cancer. To assess whether rDNA hypermethylation was a prognostic indicator for ovarian cancer patients, survival analyses were done. First, a methylation level of 0.5 was set as a cutoff as this level gave the best discrimination between long-and short-survival groups. Kaplan-Meier survival curves showed that patients with high 28S methylation had longer progression-free survival (P = 0.0014) and overall survival (P = 0.0196) than patients with low 28S methylation (Fig. 3B and D) . Although the 18S methylation was not significantly different between these two groups of patients, patients with high 18S methylation *HR with 95% confidence interval, which means that an individual with an 18S methylation level equal to 1 will be 0.259 times less likely to die than an individual with an 18S methylation level equal to 0. cUnivariate Cox analysis was done using rDNA methylation level as a continuous variable. bAverage methylation value of 18S and 28S. tended to have longer survival (Fig. 3A and C) . We next compared rDNA methylation levels between extreme survival groups (V12 versus z84 months). Patients with long progression-free survival had significantly higher 18S and 28S methylation level (P = 0.01 and 0.001, respectively; Table 1 ; Fig. 4A and B). For patients with long overall survival, a higher level of 28S methylation was observed (P = 0.03) but no increase in the level of 18S methylation was seen (Table 1 ; Fig. 4C and D) .
To exclude the possibility that the above approaches, which were based on a cutoff value or extreme survival groups, may have biased the data analysis, a univariate analysis to analyze rDNA methylation on a continuous scale was done. The results from Cox proportional hazards model are shown in Table 2 . Both 18S and 28S hypermethylation can efficiently predict progression-free survival [hazard ratios (HR) of 0.259 and 0.264; P = 0.042 and 0.008, respectively] but not overall survival (P = 0.133 and 0.086 for 18S and 28S HR, respectively). This result is essentially similar to the Kaplan-Meier finding in that higher levels of rDNA methylation were associated with longer survival. We also did multivariate analysis to assess independent predictive values of rDNA hypermethylation (as continuous variables), age at diagnosis, and clinical stage on progression-free survival and overall survival by the Cox proportional hazards model (Table 3) . rDNA methylation was a significant prognostic factor in predicting progression-free survival (P = 0.018) but not significant for overall survival (P = 0.091). As expected, age was also a significant prognostic factor for overall survival (P = 0.018). Clinical stage was not significant for progression-free survival and overall survival (P = 0.709 and P = 0.415, respectively).
Hypermethylated genes have been widely used as markers for early detection, diagnosis, and prognosis of cancer (25) , and the methylation status of MGMT was recently shown to predict brain tumor response to chemotherapy (26) . To date, most studies have associated DNA hypermethylation in single-copy tumor suppressor gene with poor prognosis. Our results, in concordance with our previous report in endometrial cancer (14) , show that hypermethylation of tandem rDNA clusters in ovarian cancer has positive prognostic potential. Conversely, Cheng et al. (27) , in an animal study, showed that low methylation of ribosomal genes in parental sperm cells may result in high incidence of neoplasm in their offspring. Taken together, our observations and those of Cheng et al. indicate that alterations in rDNA methylation play a role in tumorigenesis. As DNA hypermethylation has been shown to affect rDNA transcription (28) , it is tempting to postulate that this methylationdependent silencing may have a negative effect on the ribosome-associated protein synthesis essential for active tumor proliferation.
DNA hypermethylation contributes, in part, to the silencing of ribosomal DNA genes in ovarian cancer cells. Because epigenetic regulation of a ribosomal gene cluster had not been previously shown in ovarian tumors, it was of interest to examine the effect of 5-azaDC on 18S and 28S rDNA demethylation. Quantitative methylation-specific PCR and quantitative reverse transcription-PCR assays were used to determine the level of rDNA methylation and gene expression in MCP3 and CP70 ovarian cancer cell lines before and after 5-azaDC treatment. As shown in Fig. 5A , the levels of 18S and 28S methylation were partially decreased after the demethylating treatment, resulting in a moderate increase in 18S and 28S gene expressions. This initial result suggests that rDNA methylation level is inversely correlated with its gene expression ( Fig. 5A and B) . It also points to other types of epigenetic modifications that may work together with DNA methylation to fully modulate rDNA expression (29) . Our future analysis will focus on investigating the role of other epigenetic mechanisms in regulating ribosomal gene transcription. In addition, functional analysis can be done to establish the relationship between epigenetic down-regulation and attenuation of the ribosomal protein synthesis machinery in cancer cells.
In conclusion, we have shown that rDNA hypermethylation is a frequent event in ovarian tumors and can serve as an independent prognostic indicator for patients. An additional study is under way to further confirm this observation in an independent cohort of ovarian cancer patients and to adapt the quantitative methylation-specific PCR assay for examining rDNA hypermethylation in serum.
